All In Biotech

Investigational drug · Phase 2

WIN378

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COPD (Chronic Obstructive Pulmonary Disease), Asthma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "WIN378"

First trial start

2025

Jul 24, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "WIN378", any sponsor or status.

Conditions studied

As listed on its trial records.

  • COPD (Chronic Obstructive Pulmonary Disease)
  • Asthma

Approved drugs for the same conditions: Asthma · COPD · Respiratory

Largest trials

Live from ClinicalTrials.gov: studies naming "WIN378" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for COPD (Chronic Obstructive Pulmonary Disease)

  • Hemay005Mufemilast, Phosphodiesterase 4 inhibitorsPhase 34 trials

    Ganzhou Hemay Pharmaceutical Co., Ltd · Moderate to Severe Ulcerative Colitis, Ulcerative Colitis (UC), COPD (Chronic Obstructive Pulmonary Disease)

  • HSK39004 DryPhase 34 trials

    Haisco Pharmaceutical Group Co., Ltd. · Chronic Obstructive Lung Disease (COLD), COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)

  • BGF MDI 320BGFPhase 33 trials

    AstraZeneca · Asthma, COPD (Chronic Obstructive Pulmonary Disease)

  • HSK39004 Dry SimulantPhase 32 trials

    Haisco Pharmaceutical Group Co., Ltd. · COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)

  • REGEND001Phase 32 trials

    Regend Therapeutics · COPD (Chronic Obstructive Pulmonary Disease), Idiopathic Pulmonary Fibrosis

  • JKN2304Phase 21 trial

    Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease), COPD

  • JKN24011Phase 21 trial

    Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease)

  • JKN2403Phase 21 trial

    Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.